EUVIMEDEUVIMED entdecken
Crossref

Evaluating the Public Health and Health Economic Impacts of Baloxavir Marboxil and Oseltamivir for Influenza Pandemic Control in China: A Cost-Effectiveness Analysis Using a Linked Dynamic Transmission–Economic Evaluation Model

Yawen Jiang iD, Jiaxin Wen, Jiatong Sun, Yuelong Shu

PharmacoEconomics · 2024

DOI: 10.1007/s40273-024-01412-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PharmacoEconomics, 2024. Verfasst von Yawen Jiang und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Public Health (Shenzhen), Sun Yat-sen University, 66 Gongchang Rd, Guangming District, Shenzhen, Guangdong, China. jiangyw26@mail.sysu.edu.…. Hauptthemen laut MEDLINE: Oseltamivir, Cost-Benefit Analysis, Influenza, Human, Antiviral Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 56 Literaturangaben. Gefördert von: Guangdong Basic and Applied Basic Research Foundation, F. Hoffmann-La Roche.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Pandemic influenza poses a recurring threat to public health. Antiviral drugs are vital in combating influenza pandemics. Baloxavir marboxil (BXM) is a novel agent that provides clinical and public health benefits in influenza treatment. METHODS: We constructed a linked dynamic transmission-economic evaluation model combining a modified susceptible-exposed-infected-recovered (SEIR) model and a decision tree model to evaluate the cost-effectiveness of adding BXM to oseltamivir in China's influenza pandemic scenario. The cost-effectiveness was evaluated for the general population from the Chinese healthcare system perspective, although the users of BXM and oseltamivir were influenza-infected persons. The SEIR model simulated the transmission dynamics, dividing the population into four compartments: susceptible, exposed, infected, and recovered, while the decision tree model assessed disease severity and costs. We utilized data from clinical trials and observational studies in the literature to parameterize the models. Costs were based on 2021 CN¥ and not discounted due to a short time-frame of one year in the model. One-way, two-way, and probabilistic sensitivity analyses were also conducted. RESULTS: The integrated model demonstrated that adding BXM to treatment choices reduced the cumulative incidence of infection from 49.49% to 43.26% and increased quality-adjusted life years (QALYs) by 0.00021 per person compared with oseltamivir alone in the base-case scenario. The intervention also amounted to a positive net monetary benefit of CN¥77.85 per person at the willingness to pay of CN¥80,976 per QALY. Sensitivity analysis confirmed the robustness of these findings, with consistent results across varied key parameters and assumptions. CONCLUSIONS: Adding BXM to treatment choices instead of only treating with oseltamivir for influenza pandemic control in China appears to be cost-effective compared with oseltamivir alone. The dual-agent strategy not only enhances population health outcomes and conserves resources, but also mitigates influenza transmission and alleviates healthcare burden.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OseltamivirCost-Benefit AnalysisInfluenza, HumanAntiviral AgentsPyridonesTriazinesDibenzothiepinsModels, EconomicMorpholinesPandemicsHumansChinaQuality-Adjusted Life YearsPublic HealthDecision TreesThiepinsCost-Effectiveness Analysis

Substanzen

OseltamivirAntiviral AgentsbaloxavirPyridonesTriazinesDibenzothiepinsMorpholinesThiepins

Autor:innen und Institutionen

  • School of Public Health (Shenzhen), Sun Yat-sen University, 66 Gongchang Rd, Guangming District, Shenzhen, Guangdong, China. jiangyw26@mail.sysu.edu.cn.
  • Gusu District Center for Disease Control and Prevention, Suzhou, Jiangsu, China.
  • School of Public Health (Shenzhen), Sun Yat-sen University, 66 Gongchang Rd, Guangming District, Shenzhen, Guangdong, China.
  • School of Public Health (Shenzhen), Sun Yat-sen University, 66 Gongchang Rd, Guangming District, Shenzhen, Guangdong, China. shuylong@mail.sysu.edu.cn.
  • Institute of Pathogen Biology, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China. shuylong@mail.sysu.edu.cn.

ORCID-Profile: Yawen Jiang

Förderung

  • Guangdong Basic and Applied Basic Research Foundation
  • F. Hoffmann-La Roche

Zitieren

APA

Jiang, Y., Wen, J., Sun, J., & Shu, Y. (2024). Evaluating the Public Health and Health Economic Impacts of Baloxavir Marboxil and Oseltamivir for Influenza Pandemic Control in China: A Cost-Effectiveness Analysis Using a Linked Dynamic Transmission–Economic Evaluation Model. PharmacoEconomics. https://doi.org/10.1007/s40273-024-01412-9

Vancouver

Jiang Y, Wen J, Sun J, Shu Y. Evaluating the Public Health and Health Economic Impacts of Baloxavir Marboxil and Oseltamivir for Influenza Pandemic Control in China: A Cost-Effectiveness Analysis Using a Linked Dynamic Transmission–Economic Evaluation Model. PharmacoEconomics. 2024. doi:10.1007/s40273-024-01412-9

BibTeX
@article{Jiang2024,
  author = {Jiang, Yawen and Wen, Jiaxin and Sun, Jiatong and Shu, Yuelong},
  title = {Evaluating the Public Health and Health Economic Impacts of Baloxavir Marboxil and Oseltamivir for Influenza Pandemic Control in China: A Cost-Effectiveness Analysis Using a Linked Dynamic Transmission–Economic Evaluation Model},
  journal = {PharmacoEconomics},
  year = {2024},
  doi = {10.1007/s40273-024-01412-9}
}
Kostenlos starten →